Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Steven C. Kao and Michael J. Boyer

Recognition of the role and importance of driver mutations in malignancy has had a major impact on the management approach for many cancers. In the case of non–small-cell lung cancer, our understanding of molecular alterations has resulted in significant advances in the treatment of subgroups of patients, such as those whose tumors have an EFGR mutation or ALK or ROS-1 gene rearrangements. For tumors with sensitizing EGFR mutations, there is strong clinical evidence that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, or afatinib significantly prolong progression-free survival (PFS) compared with platinum doublet chemotherapy.


Επικοινωνήστε με το Ινστιτούτο Μοριακής Ιατρικής & Βιοϊατρικής Έρευνας



Εγγραφείτε στα Newsletter μας και μείνετε ενημερωμένοι!
Συμφωνώ με την πολιτική απορρήτου


Για οποιαδήποτε ερώτηση σας μπορείτε να επικοινωνήσετε μαζί μας στα παρακάτω στοιχεία.


Email: info@imibe.org